国际检验医学杂志
國際檢驗醫學雜誌
국제검험의학잡지
INTERNATIONAL JOURNAL OF LABORATORY MEDICINE
2014年
23期
3156-3158
,共3页
淋巴细胞参数%XE-2100 血液分析仪%临床应用
淋巴細胞參數%XE-2100 血液分析儀%臨床應用
림파세포삼수%XE-2100 혈액분석의%림상응용
iymphocyte parameters%sysmex XE-2100 hematology analyzer%clinical application
目的：探讨淋巴细胞参数在淋巴细胞增殖及反应性增生疾病筛查中的应用。方法选取健康对照组128例、淋巴瘤患者100例、多发性骨髓瘤（MM）患者35例、淋巴细胞反应性增生（RL）患者34例、慢性淋巴细胞白血病（CLL）患者5例。分别用 Sysmex XE-2100血液分析仪进行外周血血细胞分析，记录相应淋巴细胞参数值，并对其进行疾病组与对照组差异比较分析；以受试者操作特性曲线（ROC 曲线）评价各淋巴细胞参数在筛选淋巴细胞增殖及反应性增生疾病患者中的作用。结果高荧光淋巴细胞（HFL）：对照组0.008±0.008，淋巴瘤组0.016±0.058，MM 组0.019±0.063，RL 组0.040±0.070，CLL 组0.388±0.158，RL 组和 CLL 组与对照组比较，差异有统计学意义（P ＜0.05）；淋巴细胞百分率（LY％）：对照组34.4％±5.9％，淋巴瘤组26.6％±13.1％，MM 组31.0％±13.1％，RL 组29.2％±15.4％，CLL 组44.5％±38.5％，淋巴瘤组与对照组比较，差异有统计学意义（P ＜0.001）；淋巴细胞结构参数-X（LY-X）：对照组833.5±22.7，淋巴瘤组867.9±28.5，MM 组867.9±26.6，RL 组859.2±27.8，CLL 组894.0±65.4，除 CLL 组外各组与对照组比较，差异有统计学意义（P ＜0.001）；淋巴细胞结构参数-Y（LY-Y）：对照组659.6±23.0，淋巴瘤组669.4±43.5，MM 组665.9±37.1，RL 组665.9±40.0，CLL 组778.4±152.1，淋巴瘤组与对照组比较，差异有统计学意义（P ＜0.05）。LY-X 筛选淋巴细胞增殖及反应性增生疾病患者 ROC 曲线 AUC＝0.819，截断值（cut-off 值）为842.5时敏感度为80.5％，特异度为60.1％。结论淋巴细胞参数，尤其是 LY-X 能敏感地反应淋巴细胞的形态变化，有助于筛选淋巴细胞增殖及反应性增生疾病患者。
目的：探討淋巴細胞參數在淋巴細胞增殖及反應性增生疾病篩查中的應用。方法選取健康對照組128例、淋巴瘤患者100例、多髮性骨髓瘤（MM）患者35例、淋巴細胞反應性增生（RL）患者34例、慢性淋巴細胞白血病（CLL）患者5例。分彆用 Sysmex XE-2100血液分析儀進行外週血血細胞分析，記錄相應淋巴細胞參數值，併對其進行疾病組與對照組差異比較分析；以受試者操作特性麯線（ROC 麯線）評價各淋巴細胞參數在篩選淋巴細胞增殖及反應性增生疾病患者中的作用。結果高熒光淋巴細胞（HFL）：對照組0.008±0.008，淋巴瘤組0.016±0.058，MM 組0.019±0.063，RL 組0.040±0.070，CLL 組0.388±0.158，RL 組和 CLL 組與對照組比較，差異有統計學意義（P ＜0.05）；淋巴細胞百分率（LY％）：對照組34.4％±5.9％，淋巴瘤組26.6％±13.1％，MM 組31.0％±13.1％，RL 組29.2％±15.4％，CLL 組44.5％±38.5％，淋巴瘤組與對照組比較，差異有統計學意義（P ＜0.001）；淋巴細胞結構參數-X（LY-X）：對照組833.5±22.7，淋巴瘤組867.9±28.5，MM 組867.9±26.6，RL 組859.2±27.8，CLL 組894.0±65.4，除 CLL 組外各組與對照組比較，差異有統計學意義（P ＜0.001）；淋巴細胞結構參數-Y（LY-Y）：對照組659.6±23.0，淋巴瘤組669.4±43.5，MM 組665.9±37.1，RL 組665.9±40.0，CLL 組778.4±152.1，淋巴瘤組與對照組比較，差異有統計學意義（P ＜0.05）。LY-X 篩選淋巴細胞增殖及反應性增生疾病患者 ROC 麯線 AUC＝0.819，截斷值（cut-off 值）為842.5時敏感度為80.5％，特異度為60.1％。結論淋巴細胞參數，尤其是 LY-X 能敏感地反應淋巴細胞的形態變化，有助于篩選淋巴細胞增殖及反應性增生疾病患者。
목적：탐토림파세포삼수재림파세포증식급반응성증생질병사사중적응용。방법선취건강대조조128례、림파류환자100례、다발성골수류（MM）환자35례、림파세포반응성증생（RL）환자34례、만성림파세포백혈병（CLL）환자5례。분별용 Sysmex XE-2100혈액분석의진행외주혈혈세포분석，기록상응림파세포삼수치，병대기진행질병조여대조조차이비교분석；이수시자조작특성곡선（ROC 곡선）평개각림파세포삼수재사선림파세포증식급반응성증생질병환자중적작용。결과고형광림파세포（HFL）：대조조0.008±0.008，림파류조0.016±0.058，MM 조0.019±0.063，RL 조0.040±0.070，CLL 조0.388±0.158，RL 조화 CLL 조여대조조비교，차이유통계학의의（P ＜0.05）；림파세포백분솔（LY％）：대조조34.4％±5.9％，림파류조26.6％±13.1％，MM 조31.0％±13.1％，RL 조29.2％±15.4％，CLL 조44.5％±38.5％，림파류조여대조조비교，차이유통계학의의（P ＜0.001）；림파세포결구삼수-X（LY-X）：대조조833.5±22.7，림파류조867.9±28.5，MM 조867.9±26.6，RL 조859.2±27.8，CLL 조894.0±65.4，제 CLL 조외각조여대조조비교，차이유통계학의의（P ＜0.001）；림파세포결구삼수-Y（LY-Y）：대조조659.6±23.0，림파류조669.4±43.5，MM 조665.9±37.1，RL 조665.9±40.0，CLL 조778.4±152.1，림파류조여대조조비교，차이유통계학의의（P ＜0.05）。LY-X 사선림파세포증식급반응성증생질병환자 ROC 곡선 AUC＝0.819，절단치（cut-off 치）위842.5시민감도위80.5％，특이도위60.1％。결론림파세포삼수，우기시 LY-X 능민감지반응림파세포적형태변화，유조우사선림파세포증식급반응성증생질병환자。
Objective To investigate the application of lymphocyte parameters in screening the lymphocyte proliferation and re-active hyperplasia disease.Methods 128 cases as the healthy control,100 cases of lymphoma,35 cases of multiple myeloma(MM), 34 cases of lymphocytes reactive hyperplasia(RL)and 5 cases of chronic lymphocytic leukemia(CLL)were selected and performed the peripheral blood cells analysis by the Sysmex XE-2100 hematology analyzer.The relevant lymphocyte parameter values were re-corded and the comparative analysis in the difference between the disease groups and the control group was performed.The role of each lymphocyte parameter in screening the lymphocyte proliferation and reactive hyperplasia diseases was evaluated by the receiver operating characteristic curve(ROC curve).Results The high fluorescence lymphocytes(HFL),in the control group was 0.008 ± 0.008,in the lymphoma group was 0.016±0.058,in the MM group was 0.019 ±0.063,in the RL group was 0.040 ±0.070,and CLL group was 0.388±0.158.Compared with control group,the difference of RL and CLL group was statistically significant(P <0.05).The percentage of lymphocytes(LY%,:the control group:34.4%±5.9%,the lymphoma group:26.6%±13.1%,the MM group:31.0%±13.1%,the RL group:29.2%±15.4% and the CLL group:44.5%±38.5%.The difference between the lympho-ma group and the control group was statistically significant(P <0.001).The lymphocytes structural parameters X(LY-X),the con-trol group:833.5 ± 22.7,the lymphoma group:867.9 ± 28.5,the MM group:867.9 ± 26.6,the RL group:859.2 ± 27.8 and the CLL group:894.0 ± 65.4.Except for the CLL group,the differences between other groups and control group were statistically significant(P <0.001).The lymphocytes structural parameters Y(LY-Y),the control group:659.6 ± 23.0,the lymphoma group:669.4 ± 43.5,the MM group:665.9 ± 37.1,the RL group:665.9 ± 40.0 and the CLL group:778.4 ± 152.1.Compared with the control group,the difference of the lymphoma group was statistically significant(P <0.05).AUC of the ROC curve in the pa-tients with lymphocyte proliferation and reactive hyperplasia disease by LY-X screening was 0.819,with the sensitivity of 80.5%and the specificity of 60.1% when cutoff value was 842.5.Conclusion The lymphocyte parameters,especially LY-X can reveal the <br> morphological changes of lymphocytes sensitively and contribute to screening the patients with lymphocyte proliferation and reactive hyperplasia disease.
